Seagen, Inc.
Bothell
WA
United States
816 articles with Seagen, Inc.
-
Talks between Merck and Seagen are heating up as the former looks to buy the latter, according to a report published by The Wall Street Journal.
-
Pharmaceutical giant Merck is exploring a possible purchase of biotech company Seagen, according to The Wall Street Journal.
-
More oncology firms presented positive developments in their respective cancer research programs at the 2022 ASCO annual meeting this week.
-
Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
6/6/2022
Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer.
-
Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
6/6/2022
Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced interim data from the innovaTV 205 trial, which included data evaluating tisotumab vedotin (TIVDAK®) in combination with pembrolizumab (Cohort E) in patients with recurrent or metastatic cervical cancer.
-
ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
6/3/2022
Seagen Inc. (Nasdaq: SGEN) today announced results from a presentation by the Children's Oncology Group (COG) of a phase 3 trial (AHOD1331) evaluating ADCETRIS® (brentuximab vedotin) in children and young adults with high-risk, previously untreated classical Hodgkin lymphoma (cHL).
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Two therapies for different cancers are moving forward in development following positive outcomes in their clinical trials ahead of the ASCO's annual meeting in early June 2022.
-
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
5/23/2022
Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA ® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer.
-
Several biopharma companies are opening the week with positive clinical trial news. Read on for updates from Cytokinetics, Concert Pharmaceuticals, Idorsia and Seagen.
-
Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
5/16/2022
Seagen Inc. announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors.
-
Clay Siegall resigned his role as president, CEO and a member of the board of directors of Seagen following domestic violence allegations. Roger Dansey will serve as interim CEO.
-
Police documents reveal a May 2 dated TRO against Siegall concerning a fourth degree domestic violence gross misdemeanor charge.
-
Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
5/9/2022
Roger Dansey, M.D., Chief Medical Officer, Appointed Interim CEO The Board of Directors of Seagen Inc. announced that President, CEO and Chairman Clay Siegall, Ph.D. is on a leave of absence.
-
Today’s announcement from Seagen’s board of directors included difficult news regarding Clay Siegall, Ph.D. Until today, Siegall served as Seagen’s President, CEO and Chairman.
-
ImmunoGen, which is developing Antibody-drug conjugates (ADCs) for the treatment of cancer, is on a hiring spree. The company is looking to hire for more than 200 positions by the end of 2022.
-
Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
4/28/2022
Seagen Inc. (Nasdaq:SGEN) today announced upcoming presentations of new data from its expanding pipeline of marketed and investigational therapies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 3-7, 2022 in Chicago.
-
Seagen Reports First Quarter 2022 Financial Results
4/28/2022
Seagen Inc. reported financial results for the first quarter ended March 31, 2022.
-
Seagen, Inc. and NovoCure Ltd. have each announced plans to open new facilities in the coming years, expanding local employment opportunities and respective presences in the biotech industry.
-
Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
4/20/2022
Seagen Inc. (Nasdaq: SGEN) today announced plans to build a new facility in Everett, Washington, to expand the company’s biomanufacturing capacity and enable the company greater control and flexibility over the production of its medicines to treat cancer.